Loss of tau rescues inflammation-mediated neurodegeneration by Nicole Maphis et al.
ORIGINAL RESEARCH
published: 03 June 2015
doi: 10.3389/fnins.2015.00196
Frontiers in Neuroscience | www.frontiersin.org 1 June 2015 | Volume 9 | Article 196
Edited by:
Ritchie Williamson,
University of Dundee, UK
Reviewed by:
Isidro Ferrer,
University of Barcelona, Spain
Efthimios M. C. Skoulakis,
Biomedical Sciences Research Center
“Alexander Fleming,” Greece
*Correspondence:
Kiran Bhaskar,
Department of Molecular Genetics
and Microbiology, University of New
Mexico, MSC08 4660, 1 University of
New Mexico, Albuquerque,
NM 87131, USA
kbhaskar@salud.unm.edu
Specialty section:
This article was submitted to
Neurodegeneration,
a section of the journal
Frontiers in Neuroscience
Received: 31 March 2015
Accepted: 18 May 2015
Published: 03 June 2015
Citation:
Maphis N, Xu G, Kokiko-Cochran ON,
Cardona AE, Ransohoff RM, Lamb BT
and Bhaskar K (2015) Loss of tau
rescues inflammation-mediated
neurodegeneration.
Front. Neurosci. 9:196.
doi: 10.3389/fnins.2015.00196
Loss of tau rescues
inflammation-mediated
neurodegeneration
Nicole Maphis 1, Guixiang Xu 2, Olga N. Kokiko-Cochran 2, Astrid E. Cardona 3,
Richard M. Ransohoff 4, Bruce T. Lamb 2 and Kiran Bhaskar 1*
1Department of Molecular Genetics and Microbiology, University of New Mexico, Albuquerque, NM, USA, 2Department of
Neurosciences, Cleveland Clinic Foundation, Cleveland, OH, USA, 3Department of Biology, University of Texas at San
Antonio, San Antonio, TX, USA, 4 Biogen Idec, Cambridge, MA, USA
Neuroinflammation is one of the neuropathological hallmarks of Alzheimer’s disease (AD)
and related tauopathies. Activatedmicroglia spatially coexist withmicrotubule-associated
protein tau (Mapt or tau)-burdened neurons in the brains of human AD and non-AD
tauopathies. Numerous studies have suggested that neuroinflammation precedes tau
pathology and that induction or blockage of neuroinflammation via lipopolysaccharide
(LPS) or anti-inflammatory compounds (such as FK506) accelerate or block tau
pathology, respectively in several animal models of tauopathy. We have previously
demonstrated that microglia-mediated neuroinflammation via deficiency of the
microglia-specific chemokine (fractalkine) receptor, CX3CR1, promotes tau pathology
and neurodegeneration in a mouse model of LPS-induced systemic inflammation. Here,
we demonstrate that tau mediates the neurotoxic effects of LPS in Cx3cr1−/− mice.
First,Mapt+/+ neurons displayed elevated levels of Annexin V (A5) and TUNEL (markers
of neurodegeneration) when co-cultured with LPS-treated Cx3cr1−/−microglia,
which is rescued in Mapt−/− neurons. Second, a neuronal population positive for
phospho-S199 (AT8) tau in the dentate gyrus is also positive for activated or cleaved
caspase (CC3) in the LPS-treated Cx3cr1−/− mice. Third, genetic deficiency for tau
in Cx3cr1−/− mice resulted in reduced microglial activation, altered expression of
inflammatory genes and a significant reduction in the number of neurons positive for
CC3 compared to Cx3cr1−/−mice. Finally, Cx3cr1−/−mice exposed to LPS displayed
a lack of inhibition in an open field exploratory behavioral test, which is rescued by tau
deficiency. Taken together, our results suggest that pathological alterations in tau mediate
inflammation-induced neurotoxicity and that deficiency ofMapt is neuroprotective. Thus,
therapeutic approaches toward either reducing tau levels or blocking neuroinflammatory
pathways may serve as a potential strategy in treating tauopathies.
Keywords: Alzheimer’s disease, tauopathies, tau protein, microglia, neuroinflammation, CX3CR1, microtubule
associated protein tau (MAPT), neurodegeneration
Introduction
Neurodegeneration is one of the prominent pathological hallmarks of Alzheimer’s disease (AD)
and numerous non-AD tauopathies (Lee et al., 2001; Cummings and Cole, 2002). While increasing
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evidence suggests that pathological modification of microtubule-
associated protein, tau (MAPT), and neuroinflammation play
a significant role in the neuronal loss observed in tauopathies
(Ishizawa and Dickson, 2001; Gerhard et al., 2004, 2006;
Wyss-Coray, 2006), the exact mechanism by which these two
pathologies result in neurodegeneration remain unclear.
Microglia, the resident inflammatory cells of the central
nervous system, monitor the brain for pathological alterations
and become activated in most neurodegenerative diseases,
including AD and other tauopathies (reviewed in McGeer
and McGeer, 2001). Microglial activation can be beneficial
or detrimental, contingent upon the context. Activation
involves morphological alterations, proliferation, phagocytosis,
migration, enhanced expression of cell surface receptors and
the production of cytokines (Wyss-Coray, 2006). One way
microglia communicate with neurons is via signaling between
the neuronally-derived chemokine fractalkine (CX3CL1) and
its G-coupled protein receptor, CX3CR1, which is expressed
exclusively by microglia within the CNS (Harrison et al.,
1998). Unlike other chemokines, CX3CL1 and its cognate
receptor CX3CR1, are a unique, one to one ligand-receptor
pair known to play an important role in neuroinflammation
and neuroprotection. First, CX3CL1 and CX3CR1 signal to
each other during chemotaxis (Bazan et al., 1997; Garton et al.,
2001). Second, exogenously added CX3CL1 is neuroprotective in
models of neuroinflammation (Meucci et al., 1998; Mizuno et al.,
2003). Third, a genetic variant with reduced levels of CX3CR1
has been associated with age-related macular degeneration in
humans (Combadiere et al., 2007). Fourth, an earlier study
from our group demonstrated that disruption of CX3CL1-
CX3CR1 signaling in Cx3cr1−/− mice (Jung et al., 2000)
induces neurotoxicity upon peripheral LPS administration.
CX3CR1 deficiency also accelerates neurodegeneration in
mouse models of Parkinson’s disease (PD) and Amyotrophic
Lateral Sclerosis (ALS) (Cardona et al., 2006). Finally, in an
earlier study we provided compelling evidence that a single
dose of LPS significantly enhanced tau phosphorylation in
CX3CR1-deficient mice (Bhaskar et al., 2010). Notably, CX3CR1
deficiency also accelerated tau phosphorylation, aggregation,
neuroinflammation as well as cognitive impairment in an
hTau mouse model of tauopathy (Bhaskar et al., 2010). Taken
together these results suggest that CX3CR1 deficiency enhances
neuroinflammation and accelerates tau hyperphosphorylation,
which may result in neurodegeneration. However, it is unclear
if tau mediates LPS-induced neurodegeneration in the CX3CR1
deficient mice.
Previous studies have suggested that tau can mediate a variety
of AD-related phenotypes and that genetic removal of tau is
Abbreviations: AD, Alzheimer’s disease; MAPT, Microtubule Associated Protein
Tau; LPS, Lipopolysaccharide; A5, Annexin V; CC3, Cleaved Caspase 3; TUNEL,
Terminal deoxynucleotidyl transferase dUTP nick end labeling; PD, Parkinson’s
disease; ALS, Amyotrophic lateral sclerosis; Aβ, amyloid beta; DIV, Days in vitro;
DG, Dentate Gyrus; KA, Kainic Acid; Veh, Vehicle; HSP60, Heat shock protein
60; TREM2, Triggering receptor expressed on myeloid cells 2; TYROBP, TYRO
protein tyrosine kinase-binding protein; DAP12, DNAX activation protein of
12 kDa; HMGB1, High mobility group 1; IL-1β, Interleukin-1β; MWM, Morris
WaterMaze; EPM, Elevated PlusMaze; NOR,Novel Object Recognition Test; OFT,
Open Field Test; p38 MAPK, p38 mitogen activated protein kinase.
neuroprotective. First, tau-deficient neurons have been shown
to be resistant to Aβ-mediated neurotoxicity (Rapoport et al.,
2002). Second, genetic deficiency of tau in an AD mouse model
improved cognitive function and reduced excitotoxic injury
(Roberson et al., 2007; Ittner et al., 2010). Third, Shipton and
colleagues recently showed that deficiency of tau protected
against Aβ-induced impairment of long-term potentiation in
hippocampal slices of wild type mice (Shipton et al., 2011).
Fourth, tau deletion has been shown to reduce Aβ-induced
defects in axonal transport (Vossel et al., 2010). Finally, a recent
study suggested that tau mitigates cognitive impairment induced
by type-1 diabetes (Abbondante et al., 2014).
On the other hand, characterization of various lines of tau
knockout mice has suggested that tau deficiency is detrimental
to the neuronal homeostasis causing axonal dysfunction,
neurodegeneration and behavioral impairment (Ahmed et al.,
2014; Lei et al., 2014).While these studies suggest that straight tau
knockouts may be detrimental in the long-term, it may provide
protection against neurotoxic insults such as Aβ. In the current
study we demonstrate that deficiency of tau in a CX3CR1-
deficient LPS model of neuroinflammation is neuroprotective.
Materials and Methods
Animals, Antibodies, and Reagents
Mapt−/− (Dawson et al., 2010; De Barreda et al., 2010), and
Cx3cr1−/− (Jung et al., 2000) (targeted deletion of Cx3cr1 via
insertion of green-fluorescence protein gene into the Cx3cr1
locus)mice weremaintained in the C57BL/6J genetic background
and were obtained from the Jackson Laboratory and Dan
Littman (HHMI, New York University School of Medicine).
Cx3cr1−/− mice were crossed to Mapt−/− mice to generate
Cx3cr1−/−/Mapt−/− mice. The University of New Mexico and
Cleveland Clinic Institutional Animal Care and Use Committees
(IACUC) approved all animal procedures.
MAPT antibody: Mouse monoclonal antibodies—AT8
(Pierce). Inflammatory markers: Rabbit polyclonal antibody
against ionized calcium binding adaptor molecule 1
(Iba1) (Wako). Apoptotic antibodies and reagents: Rabbit
monoclonal antibody against CC3 (clone 5A1E; Asp175, Cell
Signaling #9664); mouse monoclonal antibody against A5
(EPR3980, Novus Biological/Biotechne); TUNEL kit (Roche; In
Situ Cell Death Detection Kit, TMR Red; Cat # 12 156 792 910).
Other antibodies: mouse monoclonal NeuN (Millipore), mouse
monoclonal antibody against microtubule-associated protein 2
(MAP2; Sigma).
Primary Cortical Neuronal Cultures
Neuronal cultures were prepared from E16.5 C57BL/6J wild-
type (referred to as Mapt+/+) or Mapt−/− mouse embryos as
previously described (Bhaskar et al., 2009). All cultures were
grown for 21 days in vitro (DIV) at 37◦C in humidified 5%
CO2/95% air prior to any treatment. Specifically, primary cortical
neurons were seeded onto poly-L-lysine coated coverslips at a
density of 1.6×105 cells/well in six-well plate for both co-culture
and immunofluorescence experiments (Figure 1A).
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FIGURE 1 | Loss of tau reduces inflammation-induced expression of
CC3 and Annexin V (A5) in primary neurons. (A) Schematic showing the
neuron-microglia co-culture experiments. Primary cortical neurons at 21 days
in vitro (DIV) (Mapt+/+ or Mapt−/−) were co-cultured with LPS (1µg/ml; 24
h)-stimulated Cx3cr1−/− microglia for 24 h. The neurons were fixed and
stained for CC3 and A5. (B,C) MAP2 positive Mapt−/− neurons show
reduced CC3 and A5 staining compared to Mapt+/+ neurons. The blue label
in the last panel shows DAPI. Scale bar 10µm. (D) The percentage of
CC3+MAP2+ and A5+MAP2+ neurons revealed a statistically significant
(**p < 0.01 for CC3; unpaired t-test; n = 3 independent experiments;
mean ± SEM) reduction for CC3+MAP2+ for Mapt−/− neurons compared
to Mapt+/+ neurons. (E) Quantification of A5+MAP2+ neurons reveals trend
toward reduced A5+MAP2+ immunoreactivity in Mapt−/− neurons
compared to Mapt+/+ neurons.
Primary Microglial Culture
Microglial cultures were prepared from post-natal day 3 (P3)
pups from Cx3cr1−/− genotype as previously described (Saura
et al., 2003). Briefly, mixed glial cells were first cultured and
grown in T-75 cm2 flask seeded at a density of 1.0 × 105 −
1.2 × 105 cells/cm2. After 14DIV, a differential trypsinization
protocol was utilized to remove the astrocytes in the flasks. The
pure population of microglia was then seeded at a density of
2×105 cells/well in a six-well plate (Figure 1A). Furthermore, the
DMEM-F12 media was replaced with Neurobasal media (with
no B27 supplement) 24 h prior to the co-culture experiment to
match the culture media of primary neurons.
Neuron-Microglia Co-Cultures
Primary neuronal and microglial cultures were prepared as
described above. 21DIV primary cortical neurons grown on a
coverslip were placed inside a six-well microplate insert, which
has a 0.02µm Anopore R© membrane in the bottom (161395;
Nunc). These inserts allow the diffusion of soluble factors
into the shared media. The inserts were then placed inside
individual wells in a six-well plate, which had LPS (1µg/ml;
for 24 h) (or vehicle) pre-treated Cx3cr1−/− or no primary
microglia, and incubated for 24 h (Figure 1A). The neurons
were fixed in 2% paraformaldehyde (PFA) and processed for
immunofluorescence analysis. All the experiments were done in
triplicate with independent cultures.
Lipopolysaccharide and Kainic Acid
Administration
Vehicle (Veh, Hank’s Balanced Saline Solution) or
lipopolysaccharide (LPS; Sigma-Aldrich, USA) (1mg/kg
body weight or b.w, LPS; intraperitoneal or i.p; one dose per
day for 3 days or 10mg/ml single dose for the gene expression
and TUNEL analysis) was injected into 2-month-old non-
transgenic C57BL/6J (also referred to as Cx3cr1+/+) and
Cx3cr1−/−/Mapt−/− mice. The doses of LPS were selected based
on a study, which reported the sub-lethal dosage (<5mg/kg
b.w.) in non-transgenic mice (Qin et al., 2007). 24 h following the
final injection, the mice were sacrificed and the right hemisphere
was drop-fixed in 4% PFA and processed for neuropathological
analysis.
Kainic acid (“KA”; Sigma, K2389) was injected
intraperitoneally as previously described (Ghosal and Pimplikar,
2011). Briefly, KA (20mg/kg b.w; i.p) was administered to
2-month-old C57Bl/6J mice. Animals were sacrificed after 3 days
and transcardially perfused with ice-cold phosphate buffer. The
brains were removed; the right hemisphere was drop-fixed in 4%
PFA and processed for neuropathological analysis.
Immunocytochemistry
For visualization of CC3 and A5 positive neurons in vitro,
primary cortical neurons were fixed with 2% PFA, blocked with
5% normal goat serum (NGS) in PBS with 0.4% Triton X-100 for
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1 h at room temperature, and incubated overnight at 4◦Cwith the
primary antibodies (in blocking buffer) against MAP2 (1:1000)
and A5 (1:1000) or MAP2 (1:1000) and CC3 (1:1000). Following
3 washes with PBS at room temperature, cells were incubated
with respective secondary antibodies conjugated to Alexa Fluor R©
488 andAlexa Fluor R© 555 (1:1000; Invitrogen) for 1 h at RT. Cells
on coverslips were subsequently washed with PBS and affixed to
glass slides via hard-set mounting media with or without DAPI
(Vector Laboratories).
Quantitative Morphometry
For quantitative morphometry, the number of MAP2+A5
and MAP2+CC3 positive neurons was quantified by scoring
five random fields per group (Mapt+/+ or Mapt−/−) on
digital images obtained on a fluorescent microscope at 40x
magnification. By assigning the total number of neurons in
each field as 100%, double positive neurons in each field were
calculated and expressed as % mean ± SEM (n = 3 independent
co-cultured experiment) of double positive cells per field.
Immunohistochemistry
Free-floating sections (30µm thick) were processed for standard
immunohistochemistry or immunofluorescence staining. The
sections were incubated in 10mM sodium citrate buffer (pH 6.0)
for 10min at 95◦C for antigen retrieval, then washed and blocked
in 5% NGS with 0.4% Triton X-100 (blocking buffer) for 1 h at
room temperature. Primary antibodies used were at the following
dilutions; AT8 at 1:250; Iba1, CC3 and A5 at 1:500; and were
incubated overnight at 4◦C. Secondary antibodies conjugated
to either Alexa Fluor R© dyes (1:1000, for immunofluorescence;
Invitrogen) or biotin (1:250, for immunohistochemistry; Vector
Laboratories) were used. Sections were then either mounted in
DAPI Hardset Reagent (for immunofluorescence) or incubated
with Avidin:Biotinylated enzyme Complex (ABC reagent, Vector
Laboratories; for immunohistochemistry) reagent for 1 h at
RT. The immunoreactive signals were revealed by developing
sections in SigmaFast R© 3,3’-diaminobenzidine (DAB) tablets
(Sigma-Aldrich). Bright field and epifluorescence images were
acquired using Leica DMR upright fluorescence/bright field
microscope. Confocal images were acquired and analyzed with
Leica TCS-SP and SP-AOBS upright confocal microscope with
Leica confocal software or a Zeiss inverted Meta confocal
microscope and Zeiss Zen software.
For double labeling with Terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) and NeuN, first the
30µm sections were incubated with 2 N HCl for 30min at 37◦C
to allow for nuclear permeabilization followed by neutralization
with 0.1M sodium borate buffer (pH 8.6) for 10min at room
temperature. After washing multiple times with PBS, the sections
were processed for antigen retrieval as described above. Then
the sections were blocked in blocking buffer and processed for
TUNEL staining as per manufacturer’s instructions (Roche).
After washing several times, the sections were processed for
double immunofluorescence with a mouse monoclonal antibody
against NeuN followed by Alexa Fluor R© 488 anti-mouse
secondary antibody. The slides were cover-slipped and imaged
as described above.
Quantitative Immunohistochemistry
Iba1+ area
Iba1 immunoreactive area was quantified using the “Area
Measure” tool in the Fiji Image J (NIH Software). First the
Iba1-immunostained sections (4 random sagittal sections/mouse
brain; n = 4mice per genotype) were imaged with a 40x objective
and were converted into 8-bit gray scale with a threshold level
kept at 89 to create a mask on the Iba1+ cells. After applying
the threshold mask, the Analyze > Measure tool was utilized to
measure the total area occupied by Iba1+ cells in each image. The
percentage of Iba1+ area was averaged for three fields per section
and all sections per mouse in a genotype. The values expressed
are % mean± SEM per 1mm2 area.
CC3+ cells in the dentate gyrus (DG)
CC3+ cells were manually scored in each digital image (obtained
at 40x magnification). Three random fields within the DG were
captured per section and three sections per mouse were scored.
A total of n = 4 per group: Cx3cr1−/− (VEH or LPS);
Cx3cr1−/−/Mapt−/− (VEH or LPS); non-transgenic (KA) were
used for the quantification. Values expressed are mean ± SEM
number of CC3+ neurons per 500µm2.
TUNEL positive cells
The number of TUNEL positive cells in the granule cell layer
of the DG were scored manually per each field (two random
fields/section; two sections per genotype) in the max-Z projected
confocal digital images taken at 65x magnification. A total of n =
4 mice per group: Cx3cr1−/− (LPS) and Cx3cr1−/−/Mapt−/−
(LPS) were used for quantification. The values expressed are the
total number of TUNEL positive cells per µm2, mean± SEM.
Gene Expression Analysis
RNA from the hemi-brain (or from co-cultured Cx3cr1−/−
microglia) was extracted using the Trizol Reagent as described
by the manufacturer (Life Technologies). Total RNA (100 ng/µL)
was converted to cDNA using the High Capacity cDNA Reverse
Transcription kit (Life Technologies, 4368813) and amplified
using specific TaqMan probes (Life Technologies, 4331182, see
Table 1) and GAPDH was used as a house-keeping gene for
normalization, on the StepOnePlus R© Life Technologies Real-
Time PCR System.
Open Field Test (OFT)
The locomotor behavior of mice was recorded with the open field
test. Briefly, each mouse was placed in an open field apparatus
equipped with 16 photo beams (San Diego Instruments, San
Diego, CA), for a single 15-min session. The time spent by each
mouse in either the central or peripheral area of the open field
was analyzed.
Statistical Analysis
Data are presented as mean ± SEM, unless otherwise noted, the
Student’s t-test (two-tailed; unpaired) at 95% confidence interval
(for two group comparison) or One-Way ANOVA followed by
Tukey or Dunnett’s post-hoc test (for multiple comparisons)
was utilized for statistical analysis. Statistical significance was
determined at p < 0.05.
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TABLE 1 | List of gene expression assays utilized.
Symbol Gene name Assay ID (Life
Technologies)
CD200R1 CD200 Receptor 1 Mm00491164_m1
Tyrobp TYRO protein tyrosine kinase binding
protein (DAP12)
Mm00449152_m1
Hmgb1 High mobility group box 1 Mm00849805_gH
Hspd1 Heat Shock Protein 1 (chaperonin, HSP60) Mm00849835_g1
IL-1β Interleukin 1 beta Mm00434228_m1
Trem2 Triggering receptor expressed on myeloid
cells 2
Mm04209424_g1
IL10RA Interleukin 10 receptor alpha Mm00434151_m1
Results
Mapt−/− Neurons are Resistant to Microglial
Neurotoxicity
To determine whether deficiency of tau in the primary cortical
neurons will provide resistance against microglial-mediated
neurotoxicity, we performed neuron-microglia co-culture
experiments. Briefly, Cx3cr1−/− primary microglia derived
from post-natal day 3 pups were cultured until 14DIV
(Saura et al., 2003; Bhaskar et al., 2010). After removal of
the astrocyte layer, pure primary microglia were seeded onto
plates. Concurrently, primary neurons derived from either non-
transgenic or tau knockout (Mapt−/−) mouse embryos (E16.5)
were cultured until 21DIV. For the co-culture experiment,
primary microglia were stimulated with 1µg/ml LPS for
24 h. Then, the primary neurons were co-cultured with the
LPS-activated microglia for 24 h. Neurons were then fixed and
processed for immunofluorescence analysis for A5 and CC3
to determine the extent of neurodegeneration (Figure 1A).
Our results suggest that Mapt+/+ neurons displayed elevated
levels of A5 and CC3 (markers of neurodegeneration) when co-
cultured with LPS-treated Cx3cr1−/− microglia (Figures 1B,C).
Interestingly, Mapt−/− neurons cultured in an identical
experimental paradigm showed significantly less A5 and CC3
positive neurons (Figures 1B,C). The anti-MAP2 antibody was
used to label neurons. Quantification revealed a statistically
significant reduction in CC3 positivity in Mapt−/− neurons
compared to Mapt+/+ neurons (Figure 1D). Notably, Mapt−/−
neurons also showed a trend toward reduced A5 positivity
compared to Mapt+/+ neurons. These results suggest that
neurons deficient for tau are resistant to CX3CR1-deficient
microglial neurotoxicity.
Genetic Deficiency of Tau in the Cx3cr1−/− Mice
Protects from LPS-Induced Neurotoxicity
Initial studies from our group examining the role of
CX3CR1 in LPS-mediated neurodegeneration (Cardona
et al., 2006) and tau hyperphosphorylation (Bhaskar et al.,
2010) have been already published. To determine whether
tau phosphorylation and neurodegeneration occur in the same
susceptible neuronal population within the hippocampus, double
immunofluorescence analysis with AT8 and CC3 antibodies
were performed in the LPS treated Cx3cr1−/− mice. Numerous
CC3+ cells were observed within the dentate gyrus (DG) of
LPS (1mg/kg b.w, daily for 3 days) injected Cx3cr1−/− mice
compared to vehicle-injected controls (Figure 2A). Notably,
LPS-induced AT8-site tau phosphorylation was observed within
the same neuronal population of DG that is also positive for CC3
(Figure 2A), suggesting that LPS administration induces both
tau phosphorylation and neurodegeneration within the same
susceptible neuronal population of Cx3cr1−/− mice.
To test whether removal of Mapt could be neuroprotective
in the LPS model in vivo, Mapt−/− mice were mated with
Cx3cr1−/− mice to generate Cx3cr1−/−/Mapt−/− mice. Three
groups of mice, Cx3cr1+/+, Cx3cr1−/− and Cx3cr1−/−/Mapt−/−
were aged to 2 months of age and challenged with LPS (1mg/kg
b.w, daily for 3 days) and examined for various measures of
neurodegeneration. Similar to a previously published report
from our group (Cardona et al., 2006), the Cx3cr1−/− mice
injected with LPS displayed numerous CC3 immunoreactive cells
within the DG (Figure 2B), while the Cx3cr1−/−/Mapt−/− mice
administered with similar dose of LPS displayed a relatively
reduced number of CC3 immunoreactive cells (Figure 2B). As a
positive control, 2-month-old non-transgenic mice administered
with kainic acid (KA, an excitotoxin) showed increased
microglial activation (Figure 3A) and CC3 immunoreactivity in
the hippocampus (Figure 2B). Upon quantification, the number
of CC3+ cells in the DG was significantly higher in the LPS
injected Cx3cr1−/− mice compared to vehicle (Veh) injected
mice (Figure 2C), which was similar to non-transgenic mice
injected with KA (Figure 2C). Interestingly, the number of CC3+
cells in the Cx3cr1−/−/Mapt−/− mice injected with LPS was
significantly lower compared to Cx3cr1−/− mice injected with
an identical dose of LPS (Figure 2C). Next, to confirm that
these CC3+ cells are indeed degenerating neurons, we performed
confocal immunofluorescence analysis using the neuronal
marker NeuN and the apoptotic marker TUNEL. The number of
NeuN positive neurons showing TUNEL positivity is significantly
higher in the molecular layer of DG in the LPS treated
Cx3cr1−/− mice compared to LPS treated Cx3cr1−/−/Mapt−/−
mice (Figure 2D). We performed quantitative morphometry to
assess the number of TUNEL and NeuN double positive neurons
in Cx3cr1−/− and Cx3cr1−/−/Mapt−/− mice injected with LPS.
We selected three random sections encompassing three random
fields within DG and we scored them manually for double
positive cells. The TUNEL positive neurons were significantly
lower in the LPS treated Cx3cr1−/−/Mapt−/− mice compared
to the LPS treated Cx3cr1−/− mice (Figure 2E). Together, these
results suggest that genetic deficiency of tau in Cx3cr1−/− mice is
protective against LPS-induced neurotoxicity in vivo.
Loss of Tau Provides Neuroprotection via
Altering the Microglial Immune Response
To determine whether the deficiency of tau in neurons
affected microglial activation state, we assessed microglial
morphology and activation status in three groups of mice:
Cx3cr1+/+, Cx3cr1−/−, and Cx3cr1−/−/Mapt−/−. We identified
microglia utilizing microglia-specific Iba1 antibody and an
activated microglia/macrophage-specific antibody CD45. The
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FIGURE 2 | Tau deficiency reduces LPS-induced neurotoxicity in
Cx3cr1−/− mice. (A) Two-month old Cx3cr1−/− mice were injected with
single dose of vehicle (left panel) or LPS (right panel) (1mg/kg b.w, daily for 3
days; i.p). Brain sections were double immune-labeled with AT8
(phospho-tau at Ser199) and CC3 antibodies. Presence of AT8 (green) and
CC3 (red, arrows) positive cells were detected only in LPS treated samples,
primarily in the same sub-population of dentate gyrus. Top panel-low
magnification; bottom panel-high magnification. Scale bar 100µm in top
panels and 20µm in bottom panels. (B) The number of cells immunoreactive
for CC3 is relatively higher in the DG of 2-month-old Cx3cr1−/− mice
administered with LPS compared to 2-month-old Cx3cr1−/− mice injected
with vehicle (Veh). Deficiency of tau in Cx3cr1−/−/Mapt−/− mice shows
markedly reduced numbers of CC3+ cells following administration of a
similar concentration of LPS. As a positive control, 2-month-old
non-transgenic mice treated with kainic acid (20mg/kg b.w, single dose; i.p.)
showed a substantial number of CC3+ cells in the DG. Scale 30µm. (C)
Quantification of CC3+ cells reveals a statistically significant (**p < 0.01;
One-Way ANOVA with Tukey multiple comparison test; n = 4 mice per group)
increase in CC3+ cells in the LPS treated Cx3cr1−/− mice compared to the
Veh treated mice. Note LPS-treated Cx3cr1−/−/Mapt−/− mice showed
significantly less CC3+ cells (**p < 0.01; One-Way ANOVA with Tukey
multiple comparison test; n = 4; mean ± SEM) compared to LPS-treated
Cx3cr1−/− mice or KA-treated mice. Other comparisons are also shown
(*p < 0.05 or **p < 0.01). (D,E) The number of NeuN+ neurons (green),
which are immunoreactive for TUNEL (red) in the granule cell layer of DG is
significantly (*p < 0.05; unpaired t-test; n = 4 mice per genotype; mean ±
SEM) higher in the LPS-treated Cx3cr1−/− mice compared to the LPS
treated Cx3cr1−/−/Mapt−/− mice. Scale bar is 50µm.
degenerating neurons were identified via CC3 and MAP2
antibodies. Genetic deficiency for Mapt in Cx3cr1−/− mice
resulted in reduced Iba1+ microglial number and activation
(appearance of swollen cell body with shorter processes)
compared to LPS treated Cx3cr1−/− mice in the CA1, CA3
and DG of hippocampus (Figure 3A). Notably, as a positive
control, Iba1+ microglia from KA injected mice displayed
a more significantly activated morphology. Interestingly, the
CA1 and CA3 neurons displayed pyknotic nuclei with cresyl
violet staining (Figure 3A). Quantification of the total Iba1
immunoreactive area within the CA1, CA3, and DG subfields in
different brain sections per mouse (n = 5 per group) revealed
a statistically significant decrease in Iba1+ area in LPS treated
Cx3cr1−/−/Mapt−/− mice compared to LPS treated Cx3cr1−/−
mice and KA treated non-transgenic mice (Figure 3B). This
suggests that the overall area occupied by microglia is reduced
in Cx3cr1−/−/Mapt−/− mice following LPS treatment indicating
a less activated status. To further confirm microglial activation,
we utilized anti-CD45 antibody. In all three sub-fields of
hippocampus (CA1, CA3, and DG), the CD45+ cells were more
numerous in LPS-treated Cx3cr1−/− mice compared to LPS-
treated Cx3cr1−/−/Mapt−/− mice (Figure 3C). Taken together
markers of microglial inflammatory response (Iba1 and CD45)
are significantly reduced because of the deficiency of tau in
LPS-treated Cx3cr1−/−/Mapt−/− mice.
Next to confirm if the alterations in Iba1+/CD45+ microglial
morphology are a true representation of their activation
status, we performed quantitative gene expression analysis
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FIGURE 3 | Tau deficiency in neurons alters microglial immune
response. (A,B) Iba1+ microglia display activated morphology in the CA1 (left
column in A), CA3 (middle column in A) and dentate gyrus (right column in A)
of 2-month-old C57BL/6 injected with KA (20mg/kg b.w, single dose; i.p) and
in 2-month-old Cx3cr1−/− mice administered with LPS (1mg/kg b.w, daily for
3 days; i.p). Note that the 2-month-old Cx3cr1−/−/Mapt−/− mice
administered with the same dose of LPS show relatively lower numbers of
Iba1+ microglia, which also appear less activated. Morphometric quantification
reveals a statistically (*p < 0.05 vs. KA treated mice; **p < 0.01 vs. LPS treated
Cx3cr1−/− mice; One-Way ANOVA with Tukey multiple comparison test;
n = 4 mice/genotype; mean ± SEM) significant decrease in the percentage of
Iba1+ area in the CA1 subfield in the LPS treated Cx3cr1−/−/Mapt−/− mice
compared to LPS treated Cx3cr1−/− mice or KA treated controls. Scale
30µm. (C) Reduced CD45+ cells in the CA1, CA3, and DG subfields in LPS
treated Cx3cr1−/−/Mapt−/− mice compared to LPS treated Cx3cr1−/−
mice. Scale bar 50µm. (D,E) Quantitative real-time PCR (qRT-PCR) analysis
for HMGB1 and HSP60 transcripts (in the vehicle-treated groups; in D) and
IL-1β, HMGB1, HSP60, CD200R1, and IL10RA (in the LPS-treated groups; in
E) revealed a significant decrease (normalized to non-transgenics; *p < 0.05;
One-Way ANOVA followed by Tukey post-hoc test; n = 4 mice per group;
mean ± SEM) in the inflammatory molecules in the hemibrains of 2-month-old
Cx3cr1−/−/Mapt−/− mice compared to Cx3cr1−/−mice.
on various inflammatory genes within the brains of LPS
treated Cx3cr1−/− and Cx3cr1−/−/Mapt−/− mice. The genes we
selected to investigate are the ones involved in neuron-microglia
communications. For example, heat shock protein 60 (HSP60),
CD22, CD200 and CD47 are secreted by neurons that interact
with their receptors present on microglial surface: Triggering
receptor expressed on myeloid cells 2 (TREM2/DAP12), CD45,
CD200R1 and CD172a, respectively (reviewed in Ransohoff and
Cardona, 2010). The other key molecule secreted by neurons
under stress is an alarmin, high mobility group 1 (HMGB1).
Among the twenty-one different inflammatory genes assessed,
we observed a statistically significant reduction in the basal
level expression of HMGB1 and HSP60 in the vehicle injected
Cx3cr1−/−/Mapt−/− mice compared to the vehicle injected
Cx3cr1−/− mice (Table 1; Figure 3D). Remarkably, following
LPS treatment the expression levels of interleukin-1β (IL-1β),
HMGB1, HSP60, CD200R1 as well as IL10 receptor alpha
chain or subunit alpha (IL10RA) were significantly lower
in Cx3cr1−/−/Mapt−/− mice compared to Cx3cr1−/− mice
(Table 1; Figure 3E). Finally to determine if the lack of tau in
neurons affects microglial activation state in our cell culture
model of LPS-induced neuroinflammation, we assessed the
expression of IL-1β in the LPS-treated Cx3cr1−/− primary
microglia that were co-cultured with Mapt+/+ or Mapt−/−
primary cortical neurons. As expected, microglia responded to
LPS, showing a significant upregulation of IL-1β expression when
they were co-cultured for 24 h with either Mapt+/+ or Mapt−/−
primary neurons (Figure 4A). However, microglia co-cultured
with Mapt−/− primary neurons showed a significantly (four-
fold) lower level of IL-1β expression compared to microglia
co-cultured with Mapt+/+ primary neurons (Figure 4A). These
results suggest that the presence or absence of tau within neurons
could affect overall microglial immune response, specifically
pertaining to IL-1β secretion.
Loss of Tau Improve Anxiety Behavior in the
Cx3cr1−/− Mice
To test whether neuroprotective effects elicited by the loss of tau
in Cx3cr1−/− mice following LPS administration translated into
functional effects, we performed various behavioral and cognitive
tests. Three groups of mice: 2 month old Cx3cr1−/− mice with
vehicle or LPS and 2 month old Cx3cr1−/−/Mapt−/− mice with
LPS were subjected to a battery of behavioral tests 7 days after
the last dose of LPS. While we did not observe any significant
alterations in Novel Object Recognition (NOR) test, Morris
Water Maze (MWM) or Elevated Plus Maze (EPM) (data not
shown), we observed significant alteration in the amount of time
the mice spent in the border vs. center of the arena in the Open
Field Test (OFT). Notably, vehicle injectedCx3cr1−/−mice spent
a majority of the time in the border of the OFT arena compared
to center, but LPS administered Cx3cr1−/− mice spent more time
in the center of the arena (Figure 4B). In contrast, LPS injected
Cx3cr1−/−/Mapt−/− mice spent more time exploring the border
and less in the center, suggesting that LPS administration leads
to lack of inhibition in Cx3cr1−/− mice, which is rescued by tau
deficiency in the Cx3cr1−/−/Mapt−/− mice (Figure 4B).
Discussion
The present study demonstrates that the loss of tau in
neurons provides protection against inflammation-induced
neurotoxicity. In the cell culture model of neurons andmicroglia,
pre-treatment of microglia with LPS leads to secretion of
cytotoxic factors, which under normal conditions enhances
tau hyperphosphorylation and results in neurodegeneration.
Mapt−/− neurons show significantly reduced levels of apoptotic
markers such as CC3 and A5. In vivo, systemic administration
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FIGURE 4 | Tau deficiency reduces microglial-IL-1β secretion in vitro
and lack of inhibition in the Cx3cr1
−/− mice following LPS
administration. (A) qRT-PCR analysis reveal LPS induced pro-IL-1β
expression in Cx3cr1−/− microglia co-cultured with Mapt+/+ neurons is
significantly (**p < 0.01; One-Way ANOVA with Tukey multiple comparison
test; n = 3 independent co-cultures; mean ± SEM) higher compared to
Cx3cr1−/− microglia co-cultured with Mapt−/− neurons. (B) Two-month-old
Cx3cr1−/− and Cx3cr1−/−/Mapt−/− mice administered with LPS (1mg/kg
b.w, daily for 3 days; i.p) or vehicle were subjected to open-field behavioral
test (for 15min) after 7 days post-LPS treatment. LPS treated Cx3cr1−/−
mice spent significantly (*p < 0.05; One-Way ANOVA with Tukey multiple
comparison test; n = 4 mice per genotype/group; mean ± SEM) less time in
the border, but more time in the center of the maze, compared to vehicle
injected Cx3cr1−/− mice or LPS injected Cx3cr1−/−/Mapt−/− mice. (C)
The working model suggests that in Cx3cr1−/−/Mapt+/+ mice, LPS
induces hyperphosphorylation (p-Tau) and possible aggregation of tau as
neurofibrillary tangles (NFTs) due in part to the sustained activation of
Cx3cr1−/− microglia. This results in upregulation of various inflammatory
regulators including neuronally derived ligands (HSP60, CD200, HMGB1),
microglial receptors (TREM2/DAP12 and CD200R), IL-1β and IL10RA that
are needed to restrain reactive microglia. Despite activation of various
negative regulatory pathways of microglia, microglia continue to show
significant activation due to the deficiency of the CX3CL1-CX3CR1
communication and LPS. Sustained activation of Cx3cr1−/− microglia leads
to neurotoxicity possibly mediated by further tau hyperphosphorylation and
by the elevated IL-1β signaling. Deficiency of tau in Cx3cr1−/−/Mapt−/−
mice show reduced microglial activation, significant reduction in inflammatory
mediators including IL-1β and HMGB1, overall decrease in neuron-microglia
restraint signaling molecules and thus prevents inflammation-induced,
tau-mediated, neurotoxicity.
of LPS causes neurotoxicity in the Cx3cr1−/− mice, which is
modulated by tau deficiency in the Cx3cr1−/−/Mapt−/− mice.
CX3CL1-CX3CR1 signaling is one of the most well studied
pathways involved in the regulation of neuron-microglia
communication. Unlike other chemokines, CX3CL1 and its
cognate receptor CX3CR1 is a unique, one to one ligand-
receptor pair, which is known to play an important role in
neuroinflammation and neuroprotection. First, CX3CL1 secreted
from neurons and signals to CX3CR1 (on microglia) during
chemotaxis (Bazan et al., 1997; Garton et al., 2001). Second,
exogenously added CX3CL1 is neuroprotective in models of in
vitro neuroinflammation (Meucci et al., 1998; Mizuno et al.,
2003). Third, a genetic variant with reduced levels of CX3CR1
has been associated with the age-related macular degeneration
in humans (Combadiere et al., 2007). Alternatively, several
studies suggest that the CX3CL1-CX3CR1 communication may
be detrimental in rodent models of acute CNS injury such
as stroke (reviewed in Sheridan and Murphy, 2013) and in
the model requiring phagocytic activity of microglia [example,
clearance of amyloid β (Aβ) plaques Fuhrmann et al., 2010; Lee
et al., 2010a].
There are two important aspects of neuron-microglia
communication that are relevant for discussion on the present
observation. First, the effects reactive Cx3cr1−/−microglia
has on the induction of tau hyperphosphorylation, neuronal
survival and homeostasis. Second, the regulation of microglial
inflammatory response by the presence of absence of neuronal
tau. For the effect of reactive microglia and neuroinflammation
on the tau pathology and neuronal survival, several previous
studies have demonstrated that neuroinflammation precedes tau
pathology in various animal models of tauopathy. First, a large
number of inflammatory cells (microglia and astrocytes) and
molecules (cytokines, chemokines, complement components,
etc...) are present at elevated levels in the AD brain (Eikelenboom
et al., 2000; Akiyama et al., 2000; McGeer and McGeer,
2001). Second, patient populations receiving sustained treatment
with NSAIDs during mid-life exhibited >50% decreased risk
of AD in retrospective studies (McGeer et al., 1996). Third,
there is increasing evidence for alterations in inflammatory
cells/molecules prior to the development of brain pathologies
in several different mouse models of AD (Qiao et al., 2001;
Li et al., 2003; Dudal et al., 2004; Kitazawa et al., 2005;
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Yoshiyama et al., 2007). Fourth, microglial activation precedes
tau pathology in a P301S mouse model of tauopathy (Yoshiyama
et al., 2007). Fifth, enhancing microglial activation via LPS
exacerbated tau pathology in both the 3xTg mouse model
of AD and rTg4510 mouse models of tauopathy (Kitazawa
et al., 2005; Lee et al., 2010b). Furthermore, blocking microglial
activation via an immunosuppressant drug (FK506) attenuated
tau pathology and extended the life span in the P301S
mouse model of tauopathy (Yoshiyama et al., 2007). Finally,
deficiency of CX3CR1 in microglia resulted in enhanced
neuroinflammation and neurotoxicity in three different animal
models of neurodegeneration (Cardona et al., 2006). Notably,
a previous study from our group has suggested that deficiency
of CX3CR1 in the hTau mouse model of tauopathy resulted in
accelerated tau pathology and cognitive impairment, which is
mediated via IL-1β-p38 mitogen activated protein kinase (p38
MAPK) signaling pathway (Bhaskar et al., 2010). It is important
to consider that in case of AD, tau hyperphosphorylation may
be triggered by Aβ, either directly via the activation of protein
kinases such as GSK3β (Ma et al., 2006) or through mediating
neuroinflammation, which can then lead to tau pathology
(reviewed in Bhaskar and Lamb, 2012). However, the extent
of tau phosphorylation directly mediated by Aβ or indirectly
via inflammatory alterations needs further study. In another
study, altered inflammatory gene expression has been reported
to precede classical hallmarks of AD (such as Aβ40, Aβ42,
membrane linked-Aβ or hyperphosphorylated tau), but correlate
with increased expression of soluble Aβ oligomers in sporadic
AD (Lopez-Gonzalez et al., 2015). Alternatively, in certain
animal models of tauopathy, inflammation has been shown to
follow, rather precede, tau pathology (reviewed in Dujardin
et al., 2015). Together, these studies suggest that microglia-
mediated neurotoxic response is a highly complex process and
may contribute to the tau pathology and neurodegeneration.
However, it is still unclear the type(s) of inflammatory responses
that precede and/or follow pathological alterations in tau. In the
present study, the presence of CC3 and AT8-site phosphorylated
tau within the same neuronal population of the hippocampus
suggests that tau hyperphosphorylation may mark susceptible
neurons that are destined to die in response to inflammation-
induced neurotoxicity. A significant neuroprotection observed
in tau negative neurons and in animal models strongly support
this possibility, but further work is necessary to confirm
how deficiency of tau would prevent the onset/progression of
apoptotic and/or other cell-death pathways within neurons in a
cell autonomous manner.
The other aspect of the neuron-microglia communication is
the regulation of the microglial activation by the presence or
absence of tau within neurons. We have observed elevated levels
of CX3CL1 in the hTau mouse model of tauopathy at the time of
early stage tau pathology (Bhaskar et al., 2010). In a recent study,
adeno-associated virus (AAV)-mediated expression of only the
soluble form of CX3CL1 resulted in reducedmicroglial activation
and tau pathology in the rTg4510 mouse model of tauopathy
(Nash et al., 2013). The primary question still unknown is how
loss of neuronal tau could result in reduced neuroinflammation
and neurodegeneration? While the CX3CL1-CX3CR1 signaling
is one of the major ways neurons communicate with microglia
to regulate microglial function, recent studies have suggested
that microglia are restrained by neurons based on various
additional inhibitory pathways initiated by neurons (reviewed
in Ransohoff and Cardona, 2010). Some of the most common
pairs of neuron-microglial inhibitory signals are: CD200-CD200
receptor (CD200R) (Hoek et al., 2000; Barclay et al., 2002), CD22-
CD45 (Mott et al., 2004), CD172A-CD47(Junker et al., 2009),
CX3CL1-CX3CR1 and HSP60–TREM2 (DAP12) (Neumann and
Takahashi, 2007; Stefano et al., 2009). Interestingly, an arginine-
to-histidine substitution at amino acid 47 (R47H) in the TREM2
gene has been shown to increase the risk of developing late-
onset AD by three-fold (Guerreiro et al., 2013; Jonsson et al.,
2013). While these ligand-receptor pairs negatively regulate
microglial activation state, it is unclear if one is efficient than the
others or if they all play similar role concurrently in dampening
microglial activation. A significant reduction in the basal levels
of HMGB1 and HSP60 in Cx3cr1−/−/Mapt−/− mice compared
to Cx3cr1−/− mice suggests that the deletion of tau in neurons
alters the levels of the neuron-derived alarmin (HMGB1) and
also down-regulates HSP60-TREM2 signaling. At this point,
it is unclear whether neurons in Cx3cr1−/− mice attempts to
keep all the ligand-receptor pairs engaged to restrain reactive
microglia, which is subdued in Cx3cr1−/−/Mapt−/− mice due
to the lack of pathological tau. On the other hand, a significant
reduction in the levels of two important pro-inflammatory
molecules (IL-1β and HMGB1) following LPS administration in
Cx3cr1−/−/Mapt−/− mice suggests that deficiency of neuronal
tau reduces microglial activation via reducing the overall levels of
IL-1β and HMGB1 (Figure 4C). While these studies, at present,
are correlative, a further characterization is needed to understand
if IL-1β and HMGB1 are the only ways to reduce microglial
activation in the absence of tau. Recent studies suggested that
misfolded tau itself could act like a trigger for microglial
activation, resulting in neuroinflammation (Zilka et al., 2009a,b,
2012). Notably, related preliminary studies in our laboratory
suggests that when the neuronal tau undergoes pathological
modification (such as hyperphosphorylation), they are secreted
out to the extracellular space via exosomes. Other groups
have also recently demonstrated the secretion of exosome-
associated pathological tau (Saman et al., 2012). Such misfolded
tau can be internalized by the microglia to induce microglial
activation and neuroinflammation (our unpublished study).
Based on these studies, we speculate that the absence of tau in
Cx3cr1−/−/Mapt−/− mice elicit a reduced microglial activation
due to unavailability of pathological tau in the extracellular space
in response to LPS-treatment. Together, these studies suggest
that tau (when pathologically modified) may directly/indirectly
regulate the microglial immune response.
In relation to the effect of inflammatory alterations and
behavioral function, several studies have observed a compelling
relationship between altered inflammatory responses and
behavior functions in various transgenic mice. First, transgenic
mice (hsIL-1ra) overexpressing human secreted interleukin-1
receptor antagonist (IL-1ra) displayed higher locomotor scores
and less anxiety in the elevated plus maze test (Oprica et al.,
2005; Spulber and Schultzberg, 2010). Second, Edaravone, a
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free radical scavenger, alleviated amyloid toxicity, reduced
neuroinflammation and improved OFT behavioral function
in APPPS1 mouse model of AD (Jiao et al., 2015). Third,
the suppression of human tau transgene with doxycycline in
rTg4510 mouse model of tauopathy, rescued behavioral function
(OFT, Y-maze and novel object recognition test) and reduced
neuroinflammation (Wes et al., 2014). Fourth, AAV-mediated
overexpression of fractalkine not only dampens microglial
activation, it also reduced neurodegeneration and rescued
cognitive deficient in rTg4510 mouse model of tauopathy
(Nash et al., 2013). Finally our previous studies suggested
that genetically inducing neuroinflammation lead to accelerated
working memory impairment in hTaumouse model of tauopathy
(Bhaskar et al., 2010). Taken together, these results suggest that
altered inflammatory response within the CNS may alter
behavioral function.
In summary, our studies suggest that the deficiency of
tau within neurons is protective against inflammation-
induced neurotoxicity. Furthermore, neurons deficient for
tau alter neuron-microglia communication with a net result of
reduced inflammatory responses, subdued neuron-microglia
molecular machinery, reduced neuroinflammation and increased
neuroprotection (Figure 4C). Therefore, future studies should
focus on either reducing tau levels or altering the neuron-
microglia pathways in the development of future therapies
against AD and related tauopathies.
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